OCT-angiography as a Pronostic Marker for Visual Impairment in Patients Undergoing Neurosurgery for Compressive Macroadenoma : a Prospective Study. (FIRST)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: ARNAUD MARTEL
- Phone Number: 0492033737
- Email: martel.a@chu-nice.fr
Study Locations
-
-
-
Nice, France, 06000
- Chu de Nice
-
Nice, France, 06001
- Hôpital Pasteur 2 - Service d'Ophtalmologie
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- pituitary compressive adenoma (for experimental group)
- pituitary non compressive adenoma
Exclusion Criteria:
- retinian disease
- amblyopia
- parkinson disease
- pregnant woman
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Non compressive adenoma
Optical Coherence Tomography Angiography without surgery
|
|
|
Experimental: Compressive adenoma
Optical Coherence Tomography Angiography before and after neurosurgery
|
adenoma removal
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change of middle deviation
Time Frame: before surgery (= inclusion), 4 months after surgery and 10 months after surgery
|
visual field evolution assessed by Middle deviation
|
before surgery (= inclusion), 4 months after surgery and 10 months after surgery
|
|
Change of visual function index
Time Frame: before surgery (= inclusion), 4 months after surgery and 10 months after surgery
|
visual field evolution assessed by visual function index
|
before surgery (= inclusion), 4 months after surgery and 10 months after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: ARNAUD MARTEL, ophtalmology department, Nice University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Site
- Neoplasms
- Endocrine Gland Neoplasms
- Nervous System Neoplasms
- Central Nervous System Neoplasms
- Hypothalamic Diseases
- Hypothalamic Neoplasms
- Supratentorial Neoplasms
- Brain Neoplasms
- Pituitary Diseases
- Pituitary Neoplasms
- Surgical Procedures, Operative
- Neurosurgical Procedures
Other Study ID Numbers
Other Study ID Numbers
- 19-AOI-06
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pituitary Adenoma
-
NCT00461188RecruitingAcromegaly | Gigantism | Familial Isolated Pituitary Adenoma | FIPA | Pituitary Adenoma Predisposition | PAP
-
NCT04335357Not yet recruitingNon-Functional Pituitary Adenoma | Pituitary Tumor, Nonfunctioning
-
NCT03807076CompletedAcromegaly Due to Pituitary Adenoma
-
NCT04121988TerminatedPituitary ACTH Secreting Adenoma
-
NCT03309319Unknown
-
NCT06163261RecruitingNon-functioning Pituitary Adenoma
-
NCT04268251CompletedCavernous Sinus Invasion by Pituitary Adenoma
-
NCT03439709Not yet recruitingAcromegaly Due to Pituitary Adenoma
-
NCT06701838Not yet recruitingPituitary Adenoma | Cushing's Disease | Hypercortisolism | Pituitary ACTH Secreting Adenoma
-
NCT07463625RecruitingCushing Disease | ACTH-producing Pituitary Tumour
Clinical Trials on Neurosurgery
-
NCT06615271Recruiting
-
NCT05264012CompletedPostoperative Pain | Neurosurgery
-
NCT05071027TerminatedAneurysm Cerebral (Unruptured)
-
NCT01169129Withdrawn
-
NCT02000570CompletedNeurosurgery in Sitting Position
-
NCT05975398RecruitingComplications | Emergency Surgery | Severe Spontaneous Intracranial Hemorrhage | Long-term Antiplatelet Treatment
-
NCT05766865CompletedComplications | Emergency Surgery | Severe Spontaneous Intracranial Hemorrhage | Long-term Antiplatelet Treatment
-
NCT02098252RecruitingArteriovenous Malformations | Unruptured Brain Arteriovenous Malformation | Ruptured Brain Arteriovenous Malformation | AVM | BAVM
-
NCT01628406Enrolling by invitationPatients Treated at the Neurosurgery Department
-
NCT00659334Terminated